title: c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
abstract: c-Abl is important for normal B-cell development, but little is known about the function of this nonreceptor tyrosine kinase in chronic lymphocytic leukemia (CLL). Therefore, the aim of the present study was to examine the clinical, therapeutic, and pathogenetic importance of c-Abl in this disease. We show that the malignant cells of CLL predominantly express the type 1b splice variant of c-Abl and that the expression of c-Abl protein is higher in CLL cells than in normal peripheral blood B cells. Moreover, we show that the levels of c-Abl protein expression correlate positively with tumor burden and disease stage, and negatively with IgV(H) mutation. We also show that STI-571, an inhibitor of c-Abl kinase activity, induces apoptosis of CLL cells with high c-Abl expression levels through a mechanism involving inhibition of nuclear factor kappaB. We conclude that overexpression of c-Abl is likely to play a pathogenetic role in CLL and that STI-571 may be of potential use in the treatment of this disease.
authors.affiliation: Department of Haematology, University of Liverpool, Daulby Street, Liverpool L69 3GA, United Kingdom. k.lin@liv.ac.uk
authors.forename: Ke
authors.initials: K
authors.lastname: Lin
authors.forename: Mark A
authors.initials: MA
authors.lastname: Glenn
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Harris
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Duckworth
authors.forename: Sally
authors.initials: S
authors.lastname: Dennett
authors.forename: John C
authors.initials: JC
authors.lastname: Cawley
authors.forename: Mirko
authors.initials: M
authors.lastname: Zuzel
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Slupsky
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D001402:B-Lymphocytes / Q000378:metabolism; D001549:Benzamides; D050438:Genes, Immunoglobulin Heavy Chain; D006801:Humans; D000068877:Imatinib Mesylate; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D009154:Mutation; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D020033:Protein Isoforms; D016315:Proto-Oncogene Proteins c-abl / Q000096:biosynthesis* / Q000235:genetics; D011743:Pyrimidines / Q000494:pharmacology*; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000096:biosynthesis
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007135:Immunoglobulin Variable Region; D016328:NF-kappa B; D010879:Piperazines; D020033:Protein Isoforms; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016315:Proto-Oncogene Proteins c-abl; D051746:ZAP-70 Protein-Tyrosine Kinase